Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Moderate Buy” from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $10.00.

A number of equities research analysts recently commented on PYXS shares. Stephens started coverage on Pyxis Oncology in a research report on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price on the stock. Stifel Nicolaus started coverage on Pyxis Oncology in a research report on Thursday, August 8th. They issued a “buy” rating and a $10.00 target price on the stock. Royal Bank of Canada boosted their target price on Pyxis Oncology from $7.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research report on Thursday. Finally, William Blair downgraded Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. StemPoint Capital LP bought a new position in Pyxis Oncology in the first quarter worth approximately $7,643,000. Ikarian Capital LLC purchased a new stake in Pyxis Oncology during the first quarter worth $7,082,000. Blue Owl Capital Holdings LP purchased a new stake in Pyxis Oncology during the second quarter worth $3,462,000. Millennium Management LLC lifted its holdings in shares of Pyxis Oncology by 125.3% during the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock valued at $4,425,000 after purchasing an additional 743,499 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Pyxis Oncology during the 3rd quarter valued at $1,405,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Stock Performance

Shares of Pyxis Oncology stock opened at $1.90 on Monday. The stock’s 50-day simple moving average is $3.64 and its 200-day simple moving average is $3.61. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.